STOCK TITAN

Cue Biopharma to Present at the Piper Sandler 33rd Annual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Cue Biopharma (CUE) announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. The company will feature a pre-recorded fireside chat, available on its website starting November 22, 2021, at 10:00 a.m. EST. Cue Biopharma is focused on developing a novel class of injectable biologics that engage T cells, aiming to transform treatments for cancer and autoimmune diseases. The archived recording will be accessible for 90 days post-event.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that it participated in a pre-recorded fireside chat as part of the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held on November 29-December 2, 2021.

The pre-recorded presentation will be available to participants during the conference and on the Events page of the Investor & Media section of the Company’s website www.cuebiopharma.com beginning today, November 22, 2021 at 10:00 a.m. EST. An archived version of the recording will be accessible for 90 days following the event.

About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body to transform the treatment of cancer, infectious disease and autoimmune disease. The company’s proprietary Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform, is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.

Headquartered in Cambridge, Massachusetts, the company is led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

For more information, visit www.cuebiopharma.com and follow us on Twitter at https://twitter.com/CueBiopharma.

Investor Contact
George B. Zavoico, Ph.D.
VP, Investor Relations & Corporate Development
Cue Biopharma, Inc.
gzavoico@cuebio.com

Media Contact
Darren Opland, Ph.D.
LifeSci Communications
darren@lifescicomms.com


FAQ

What is Cue Biopharma's participation in the Piper Sandler Virtual Healthcare Conference?

Cue Biopharma (CUE) will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021.

When will Cue Biopharma's presentation be available?

Cue Biopharma's pre-recorded fireside chat will be available starting November 22, 2021, at 10:00 a.m. EST.

Where can I find Cue Biopharma's conference presentation?

The presentation will be accessible on Cue Biopharma's website under the Investor & Media section.

How long will Cue Biopharma's conference recording be available?

The archived version of the recording will be accessible for 90 days following the event.

What is Cue Biopharma's focus in biopharmaceuticals?

Cue Biopharma is focused on developing injectable biologics to engage T cells for treating cancer, infectious diseases, and autoimmune diseases.

Cue Biopharma, Inc.

NASDAQ:CUE

CUE Rankings

CUE Latest News

CUE Stock Data

78.87M
60.21M
0.55%
25.96%
3.23%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOSTON